update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
Published 1 year ago • 302 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
17:11
emerald lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. virginia kaklamani
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
3:24
'tumors just vanished': cancer patients now in remission after drug trial
-
40:55
intel emerald rapids cpu upgrades
-
13:37
upgraded two trees sapphire pro 3d printer with e3dv6 hotend
-
30:44
what's new for the patient with er /her2- mbc progressing on cdk 4/6 inhibitor therapy? expert pe...
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
4:17
puccini: early metabolic response predicts survival in patients with mbc receiving cdk4/6 inhibitors
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
1:32
elacestrant
-
2:37
elacestrant: a new weapon against advanced estrogen receptor-positive breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
1:41
dr. harold j. burstein on cdk4/cdk6 inhibitor abemaciclib in breast cancer
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast